摘要
目的观察缬沙坦对2型糖尿病早期糖尿病肾病患者血清超敏C反应蛋白（hs—CRP）水平的影响。方法随机选取在我院门诊治疗的2型糖尿病患者80例，分为观察组和对照组各40例。对照组在血压升高时使用非ARB或ACEI类药进行控制，观察组在此基础上口服缬沙坦片80mg／d。定期检测两组患者各项血检指标，统计hs—CRP水平的变化及不良反应情况。结果两组患者治疗后hs—CRP水平较治疗前均明显下降（P〈0．05），组问比较差异有显著性（P〈0．05）。观察组1例血管性水肿，无干咳、血管神经性水肿等不良反应；对照组咳嗽3例、一过性头痛头晕3例、皮肤瘙痒2例。结论缬沙坦可显著降低2型糖尿病早期糖尿病肾病患者血清hs—CRP水平。
Objective To explore the influence of Valsartan on serum hs-CRP levels in type 2 diabetic patients with early diabetic nephropathy.Methods 80 cases of patients with type 2 diabetes patients treated in our hospital were randomly selected and divided into the observation group and control group, with 40 cases for each group. The observation group used Valsartan tablets 80 mg/d, the control group was under the BP control （ No ARB or ACEI ）. Hs-CRP level after treatment and adverse reaction of the two groups were compared.Results Hs-CRP level in two groups after the treatment decreased, the difference was statistically significant compared with that before the treatment（P〈0.05）. Also the difference between groups was significant（P〈0.05）. Conclusions Valsartan can significantly reduce the levels of serum hs-CRP in type 2 diabetes patients with early diabetic nephropathy.
出处
《国际医药卫生导报》
2012年第24期3570-3572,共3页
International Medicine and Health Guidance News
